Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Revenue (2016 - 2025)

Historic Revenue for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to $30.6 million.

  • Gyre Therapeutics' Revenue rose 1991.53% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.3 million, marking a year-over-year increase of 212.5%. This contributed to the annual value of $105.8 million for FY2024, which is 678.1% down from last year.
  • Per Gyre Therapeutics' latest filing, its Revenue stood at $30.6 million for Q3 2025, which was up 1991.53% from $26.8 million recorded in Q2 2025.
  • Gyre Therapeutics' Revenue's 5-year high stood at $101.5 million during Q4 2022, with a 5-year trough of $794000.0 in Q1 2022.
  • Moreover, its 5-year median value for Revenue was $25.5 million (2024), whereas its average is $24.0 million.
  • Its Revenue has fluctuated over the past 5 years, first plummeted by 9103.63% in 2021, then soared by 405967.21% in 2022.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Revenue stood at $2.4 million in 2021, then surged by 4059.67% to $101.5 million in 2022, then tumbled by 73.25% to $27.1 million in 2023, then rose by 2.67% to $27.9 million in 2024, then increased by 9.66% to $30.6 million in 2025.
  • Its last three reported values are $30.6 million in Q3 2025, $26.8 million for Q2 2025, and $22.1 million during Q1 2025.